NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.8300
+0.0700 (9.21%)
At close: Apr 2, 2026, 4:00 PM EDT
0.7972
-0.0328 (-3.95%)
After-hours: Apr 2, 2026, 4:18 PM EDT

NeuroSense Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-11.13-10.21-10.11-10.49-3.22
Depreciation & Amortization
0.020.020.020.010
Loss (Gain) From Sale of Assets
----0.01
Stock-Based Compensation
2.140.561.541.731.22
Other Operating Activities
-0.050.28-1.720.040.18
Change in Accounts Payable
-0.36-0.30.960.46-0.02
Change in Other Net Operating Assets
1.71-0.480.950.640.29
Operating Cash Flow
-7.67-10.14-8.35-7.62-1.54
Capital Expenditures
-0.01-0-0.03-0.07-0.02
Investment in Securities
-03.5-3.52-
Investing Cash Flow
-0.0103.47-3.59-0.02
Issuance of Common Stock
4.5511.34.343.8711.9
Other Financing Activities
-0.12-0.39-0.36-0.1-
Financing Cash Flow
4.4310.913.983.7711.9
Foreign Exchange Rate Adjustments
0.04-0.040.01-0.090.02
Net Cash Flow
-3.210.74-0.9-7.5210.36
Free Cash Flow
-7.68-10.14-8.38-7.69-1.56
Free Cash Flow Per Share
-0.30-0.55-0.61-0.67-0.25
Levered Free Cash Flow
-5.94-7.83-4.26-3.8-0.47
Unlevered Free Cash Flow
-5.91-7.83-4.26-3.8-0.47
Change in Working Capital
1.34-0.781.911.10.27
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q